Compare SRFM & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRFM | RNA |
|---|---|---|
| Founded | 2011 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.5M | 141.3M |
| IPO Year | 2023 | 2025 |
| Metric | SRFM | RNA |
|---|---|---|
| Price | $0.69 | $8.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.93 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.1M | 221.6K |
| Earning Date | 11-05-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $106,557,000.00 | N/A |
| Revenue This Year | $21.73 | $88.07 |
| Revenue Next Year | $26.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $7.49 |
| 52 Week High | $3.73 | $73.06 |
| Indicator | SRFM | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 53.17 |
| Support Level | $0.66 | $7.56 |
| Resistance Level | $0.75 | $14.05 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 19.19 | 79.33 |
Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.